Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events

Onco-cardiology recently emerged as a novel discipline to provide effective cardioprotective care against cancer therapeutics-related cardiac adverse events (CAEs) and support the continuity of optimal cancer treatment. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and drama...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Hiroshi, Akazawa, Hiroshi, Ishida, Junichi, Komuro, Issei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118963/
https://www.ncbi.nlm.nih.gov/pubmed/33997442
http://dx.doi.org/10.31662/jmaj.2021-0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118963/
https://www.ncbi.nlm.nih.gov/pubmed/33997442
http://dx.doi.org/10.31662/jmaj.2021-0001

Ejemplares similares